Colm Morrissey

Summary

Publications

  1. pmc Single cell transcriptomic analysis of prostate cancer cells
    Christopher J Welty
    Department of Urology, University of Washington, Seattle, WA, USA
    BMC Mol Biol 14:6. 2013
  2. pmc Effects of androgen deprivation therapy and bisphosphonate treatment on bone in patients with metastatic castration-resistant prostate cancer: results from the University of Washington Rapid Autopsy Series
    Colm Morrissey
    Department of Urology, University of Washington, Seattle, WA 98195, USA
    J Bone Miner Res 28:333-40. 2013
  3. pmc The expression of osteoclastogenesis-associated factors and osteoblast response to osteolytic prostate cancer cells
    Colm Morrissey
    Department of Urology, University of Washington, Seattle, Washington 98195, USA
    Prostate 70:412-24. 2010
  4. doi request reprint Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases
    Sandy R Larson
    Department of Urology, University of Washington, Seattle, Washington 98195, USA
    Prostate 73:932-40. 2013
  5. pmc Bone morphogenetic protein 7 is expressed in prostate cancer metastases and its effects on prostate tumor cells depend on cell phenotype and the tumor microenvironment
    Colm Morrissey
    Department of Urology, University of Washington, Seattle, WA 98195, USA
    Neoplasia 12:192-205. 2010
  6. pmc Inhibition of angiopoietin-2 in LuCaP 23.1 prostate cancer tumors decreases tumor growth and viability
    Colm Morrissey
    Department of Urology, University of Washington, Seattle, WA 98195, USA
    Prostate 70:1799-808. 2010
  7. pmc Androgen receptor variants occur frequently in castration resistant prostate cancer metastases
    Xiaotun Zhang
    Department of Urology, University of Washington, Seattle, Washington, United States of America
    PLoS ONE 6:e27970. 2011
  8. doi request reprint Tumour cell survival mechanisms in lethal metastatic prostate cancer differ between bone and soft tissue metastases
    Canan Akfirat
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    J Pathol 230:291-7. 2013
  9. pmc Integrin alpha2beta 1 (α2β1) promotes prostate cancer skeletal metastasis
    Joseph L Sottnik
    Department of Urology, The University of Michigan, Ann Arbor, MI 48109, USA
    Clin Exp Metastasis 30:569-78. 2013
  10. pmc Prostate cancer cell phenotypes based on AGR2 and CD10 expression
    Melissa E Ho
    Department of Urology, University of Washington, Seattle, WA 98195 6100, USA
    Mod Pathol 26:849-59. 2013

Collaborators

Detail Information

Publications16

  1. pmc Single cell transcriptomic analysis of prostate cancer cells
    Christopher J Welty
    Department of Urology, University of Washington, Seattle, WA, USA
    BMC Mol Biol 14:6. 2013
    ..A high stringency threshold, a mean Alexa Fluor® 3 signal intensity above 300, was used for gene detection. Relative expression levels were validated for select genes using real-time PCR (RT-qPCR)...
  2. pmc Effects of androgen deprivation therapy and bisphosphonate treatment on bone in patients with metastatic castration-resistant prostate cancer: results from the University of Washington Rapid Autopsy Series
    Colm Morrissey
    Department of Urology, University of Washington, Seattle, WA 98195, USA
    J Bone Miner Res 28:333-40. 2013
    ..Furthermore, in this cohort of patients, BP treatment increased BV and did not decrease the number of osteoclasts in prostate cancer bone metastases compared with bone metastases from patients who did not receive BP...
  3. pmc The expression of osteoclastogenesis-associated factors and osteoblast response to osteolytic prostate cancer cells
    Colm Morrissey
    Department of Urology, University of Washington, Seattle, Washington 98195, USA
    Prostate 70:412-24. 2010
    ..Tumor cells replace bone marrow and can elicit an osteoblastic, osteolytic, or mixed bone response. Our objective was to elucidate the mechanisms and key factors involved in promoting osteoclastogenesis in PCa bone metastasis...
  4. doi request reprint Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases
    Sandy R Larson
    Department of Urology, University of Washington, Seattle, Washington 98195, USA
    Prostate 73:932-40. 2013
    ..We determined whether previously identified and/or novel proteins were associated with the osteoblastic or osteolytic response in clinical specimens of PCa bone metastases...
  5. pmc Bone morphogenetic protein 7 is expressed in prostate cancer metastases and its effects on prostate tumor cells depend on cell phenotype and the tumor microenvironment
    Colm Morrissey
    Department of Urology, University of Washington, Seattle, WA 98195, USA
    Neoplasia 12:192-205. 2010
    ..Further studies are needed to identify changes in BMP-7 signaling that lead to the loss of its control of proliferation during PCa progression...
  6. pmc Inhibition of angiopoietin-2 in LuCaP 23.1 prostate cancer tumors decreases tumor growth and viability
    Colm Morrissey
    Department of Urology, University of Washington, Seattle, WA 98195, USA
    Prostate 70:1799-808. 2010
    ..Therefore, we hypothesized that the inhibition of angiopoietin-2 activity in PCa will impede angiogenesis, tumor growth, and alter bone response in vivo...
  7. pmc Androgen receptor variants occur frequently in castration resistant prostate cancer metastases
    Xiaotun Zhang
    Department of Urology, University of Washington, Seattle, Washington, United States of America
    PLoS ONE 6:e27970. 2011
    ..Since specific antibodies detecting all C-terminal truncated AR variants are not available, our aim was to develop an approach to assess the prevalence and function of AR variants in prostate cancer (PCa)...
  8. doi request reprint Tumour cell survival mechanisms in lethal metastatic prostate cancer differ between bone and soft tissue metastases
    Canan Akfirat
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    J Pathol 230:291-7. 2013
    ..Altogether, this suggests that optimal therapeutic inhibition may require combinations of drugs that target both bone and soft tissue-specific survival pathways...
  9. pmc Integrin alpha2beta 1 (α2β1) promotes prostate cancer skeletal metastasis
    Joseph L Sottnik
    Department of Urology, The University of Michigan, Ann Arbor, MI 48109, USA
    Clin Exp Metastasis 30:569-78. 2013
    ..Taken together, these data support that α2β1 integrin is needed for the efficient metastasis of PCa cells to the skeleton...
  10. pmc Prostate cancer cell phenotypes based on AGR2 and CD10 expression
    Melissa E Ho
    Department of Urology, University of Washington, Seattle, WA 98195 6100, USA
    Mod Pathol 26:849-59. 2013
    ..It appears that AGR2 has a protective function in primary tumors but may have a role in the distal spread of tumor cells...
  11. pmc Effect of artemisinin derivatives on apoptosis and cell cycle in prostate cancer cells
    Colm Morrissey
    Genitourinary Cancer Research Laboratory, Department of Urology, University of Washington, Seattle, WA 98195, USA
    Anticancer Drugs 21:423-32. 2010
    ..This study shows the potential use of artemisinin derivatives as therapeutic candidates for PCa and warrants the initiation of preclinical studies...
  12. pmc Histopathological assessment of prostate cancer bone osteoblastic metastases
    Martine P Roudier
    Department of Pathology, University of Washington and Research Service, Seattle, Washington, USA
    J Urol 180:1154-60. 2008
    ..The discrepancy between the radiological and clinical aspects of those events is not well understood. We better characterized the histopathology of bone processes in prostate cancer bone metastases...
  13. pmc Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers
    Akash Kumar
    Department of Genome Sciences, University of Washington, Seattle, WA 98105, USA
    Proc Natl Acad Sci U S A 108:17087-92. 2011
    ..Our results also suggest that increasingly deep catalogs of human germline variation may challenge the necessity of sequencing matched tumor-normal pairs...
  14. doi request reprint Circulating tumor cells as a marker of response: implications for determining treatment efficacy and evaluating new agents
    Christina Economos
    Department of Urology, University of Washington Medical Center, Seattle, Washington, USA
    Curr Opin Urol 22:190-6. 2012
    ..To assess the current and future potential of using circulating tumor cells (CTC) as a biomarker to assess staging/prognosis and treatment efficacy...
  15. ncbi request reprint Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases
    Colm Morrissey
    Genitourinary Cancer Research Laboratory, Department of Urology, University of Washington, Seattle, WA 98195, USA
    Clin Exp Metastasis 25:377-88. 2008
    ..In addition, the resulting tumor-associated microvessel density and distribution was significantly different between liver and bone metastasis possibly in response to the protein expression changes detailed above...
  16. pmc Circulating microRNA Profiling Identifies a Subset of Metastatic Prostate Cancer Patients with Evidence of Cancer-Associated Hypoxia
    Heather H Cheng
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America Department of Medicine, University of Washington, Seattle, Washington, United States of America
    PLoS ONE 8:e69239. 2013
    ....